Allergan CEO Brent Saunders’ meteoric rise through pharma’s chief exec ranks is paying off, and in a big way. If he’s let go after AbbVie’s $63 billion takeover of the California company goes through, Saunders will net a cool $38.7
read moreNovartis has said it shuffled staff at its under-the-gun gene therapy unit AveXis. Now we know who and when, at least when it comes to its top scientific leaders. A Novartis research exec, Page Bouchard, took the R&D helm at
read moreDr. Reddy’s, which has been dealing with repeated manufacturing setbacks from the FDA, is now facing a new regulatory challenge. It has received a complete response letter for two potentially very lucrative products, generic versions of Teva’s Copaxone and Merck’s
read moreRegeneron is humming along on the strength of flagship eye med Eylea and fast-launching immunology drug Dupixent. Now, the drugmaker is dropping $800 million into its New York operations to keep up with the growth. Regeneron is planning a statewide
read moreIn the red-hot market for PARP inhibitors, AstraZeneca and Merck’s contender Lynparza is ahead of rival products from GlaxoSmithKline and Clovis Oncology—but not comfortably ahead. That may change, though, thanks to news from a key clinical trial in ovarian cancer
read moreTwo new drugs, mAb114 and REGN-EB3, have been found to dramatically cut mortality from Ebola. More: Ebola ‘no longer incurable’ Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals